Cargando…

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Trachana, M, Triantafyllou, P, Vraka, A, Kaitalidou, E, Pratsidou-Gertsi, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194501/ http://dx.doi.org/10.1186/1546-0096-9-S1-P149

Ejemplares similares

A biopsychosocial approach to parents of children with juvenile idiopathic arthritis
por: Georgiadou, Z, et al.
Publicado: (2011)

Long-term impact of juvenile idiopathic arthritis in the Greek adults' psychosocial life
por: Dimopoulou, Despoina, et al.
Publicado: (2014)

The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008)

Clinical remission off medication in greek adults with juvenile idiopathic arthritis during a 17 year follow-up period
por: Dimopoulou, Despoina, et al.
Publicado: (2014)

PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
por: Pratsidou-Gertsi, P, et al.
Publicado: (2013)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
por: Diafa, K, et al.
Publicado: (2011)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

The portrait of Familial Mediterranean Fever in N. Greek pediatric patients: a 30-year experience
por: Pratsidou-Gertsi, P, et al.
Publicado: (2015)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
por: Cimaz, Rolando, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
por: Tzimouli, V, et al.
Publicado: (2008)

Chronic recurrent multifocal osteomyelitis in N. Greece: disease burden in pediatric patients
por: Trachana, M, et al.
Publicado: (2015)

Impact of biologics on growth in children with juvenile idiopathic arthritis
por: Uettwiller, F, et al.
Publicado: (2011)

Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population
por: Goulielmos, G. N., et al.
Publicado: (2016)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
por: Radziszewska, Anna, et al.
Publicado: (2014)

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
por: Verazza, Sara, et al.
Publicado: (2014)

PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
por: Susic, G, et al.
Publicado: (2013)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
por: Anink, J, et al.
Publicado: (2013)

Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
por: Sara, De Sanctis, et al.
Publicado: (2011)

B lymphocyte stimulator, interferon-α and HMGB 1 interrelation in childhood onset systemic lupus erythematosus: associations with disease activity and severity
por: Kanakoudi-Tsakalidou, Florence, et al.
Publicado: (2014)

Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis
por: Koutsonikoli, Artemis, et al.
Publicado: (2020)

Long term functional outcome and quality of life of patients with refractory juvenile idiopathic arthritis treated with etanercept: results of the dutch arthritis and biologicals in children register
por: Anink, Janneke, et al.
Publicado: (2014)

PReS-FINAL-2299: Novel biomarkers for the assessment of pediatric systemic lupus erythematosus nephritis (preliminary report)
por: Koutsonikoli, A, et al.
Publicado: (2013)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

PReS-FINAL-2098: Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 313 patients
por: Verazza, S, et al.
Publicado: (2013)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Phenotypes of juvenile idiopathic arthritis
por: Rokhlina, Faina, et al.
Publicado: (2014)

Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy
por: Nikishina, I, et al.
Publicado: (2008)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l2iosg2i79in5n2vrnqvtpfcuj